抗GPRC5D CAR-T细胞作为抗BCMA CAR-T治疗后进展的多发性骨髓瘤患者的挽救治疗:单中心、单臂、2期试验
这项在中国徐州医科大学附属医院开展的单中心、单臂2期试验,纳入37例抗BCMA CAR-T治疗后进展的复发或难治性多发性骨髓瘤患者,接受单次静脉输注抗GPRC5D CAR-T细胞2×10^6个/kg。中位随访12.6个月,总缓解率为84%(95%CI 68-94),13例(35%)达完全缓解或更好;常见3-4级不良事件为血液学毒性,细胞因子释放综合征发生26例(70%),无治疗相关死亡。
要点
- 抗GPRC5D CAR-T挽救治疗总缓解率84%,13例(35%)达完全缓解或更好。
- 3-4级血液学毒性常见:白细胞减少92%、淋巴细胞减少97%、中性粒细胞减少78%。
- 细胞因子释放综合征70%,3级仅5%;1例1级免疫效应细胞相关神经毒性综合征;无治疗相关死亡。
核心结论
- 抗GPRC5D CAR-T挽救治疗诱导了高缓解率,可能成为抗BCMA CAR-T治疗后进展的复发或难治性多发性骨髓瘤患者的潜在治疗选择。
- 作者认为需要进一步研究以确立该治疗方法的长期疗效和安全性。
研究设计与样本
- 单中心、开放标签、单臂2期试验,在中国徐州医科大学附属医院开展。
- 纳入18-70岁、抗BCMA CAR-T治疗后进展、预期寿命超过12周且无活动性感染或严重肝、心等疾病的复发或难治性多发性骨髓瘤患者。
- 患者接受单次静脉输注抗GPRC5D CAR-T细胞2×10^6个/kg。
- 主要终点为总缓解率,包括严格完全缓解、完全缓解、非常好的部分缓解和部分缓解,依据国际骨髓瘤工作组标准缓解评估标准。
- 2021年12月1日至2024年5月1日筛查42例,37例入组并接受抗GPRC5D CAR-T细胞治疗。
主要发现
- 中位年龄59岁(IQR 51-65),37例中男性17例(46%)、女性20例(54%),均为亚洲人。
- 中位随访12.6个月(IQR 8.2-20.8),总缓解率为84%(95%CI 68-94,37例中31例),包括13例(35%)完全缓解或更好。
- 最常见的3-4级不良事件为血液学毒性:白细胞减少34例(92%)、淋巴细胞减少36例(97%)、中性粒细胞减少29例(78%)、贫血23例(62%)、血小板减少23例(62%),分母均为37例。
- 37例中26例(70%)发生细胞因子释放综合征,其中2例(5%)为3级;观察到1例1级免疫效应细胞相关神经毒性综合征。
- 试验中无治疗相关死亡。
关键数值与推荐
- 总缓解率84%(95%CI 68-94,37例中31例),包括13例(35%)完全缓解或更好。
- 3-4级白细胞减少34例(92%)、淋巴细胞减少36例(97%)、中性粒细胞减少29例(78%)、贫血23例(62%)、血小板减少23例(62%),分母均为37例。
- 细胞因子释放综合征26例(70%),3级2例(5%);1级免疫效应细胞相关神经毒性综合征1例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要进一步研究以确立该治疗方法的长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with multiple myeloma progression after anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, the optimal salvage treatment strategies remain unclear. GPRC5D-directed CAR T cell might be a potential option. The aim of this trial was to investigate the activity and safety of anti-GPRC5D CAR T cells in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy. METHODS: In this phase 2, open-label, single-arm, phase 2 trial, at the Affiliated Hospital of Xuzhou Medical University in China, we enrolled patients (aged 18-70 years old) with relapsed or refractory multiple myeloma who had progressed disease after anti-BCMA CAR T-cell therapy and a life expectancy of more than 12 weeks without active infections, serious liver, heart, or other diseases. Patients were assigned to receive a single dose of intravenous anti-GPRC5D CAR T cell at 2 × 106 cells per kg. The primary endpoint was the overall response rate, including stringent complete response, complete response, very good partial response, and partial response, according to the standard International Myeloma Working Group response assessment criteria. Activity and safety analyses were done in the patients who received a dose of anti-GPRC5D CAR T cell as defined in the protocol. This trial is registered with the Chinese Clinical Trial Registration Center, ChiCTR2100048888, and is ongoing. FINDINGS: Between Dec 1, 2021, and May 1, 2024, 42 patients were screened, 37 were enrolled and received anti-GPRC5D CAR T-cell therapy. Median age was 59 years (IQR 51-65), 17 (46%) of 37 patients were male and 20 (54%) female. All patients were Asian. At a median follow-up of 12·6 months (IQR 8·2-20·8), the overall response rate was 84% (95% CI 68-94, 31 of 37 patients), including 13 (35%) complete responses or better. The most common grade 3-4 adverse events were haematological toxicities, including leukopenia (34 [92%] of 37 patients), lymphopenia (36 [97%]), neutropenia (29 [78%]), anaemia (23 [62%]), and thrombocytopenia (23 [62%]). 26 (70%) of 37 patients had cytokine release syndrome, which was of grade 3 in two (5%) patients. One case of grade 1 immune effector cell-associated neurotoxicity syndrome was observed. There were no treatment-related deaths in the trial. INTERPRETATION: Anti-GPRC5D CAR T-cell salvage therapy induced a high response rate, and could be a potential treatment option in relapsed or refractory multiple myeloma patients who have progressed after anti-BCMA CAR T-cell treatment. Further investigations are warranted to establish the long-term efficacy and safety of this therapeutic approach. FUNDING: National Natural Science Foundation of China and the General Project of Jiangsu Commission of Health.
引用
- Xia J, Sun Q, Zhou D, et al. Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2025. PMID: 40228504. doi:10.1016/S2352-3026(25)00048-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。